Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Gottlieb

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
American Health & Drug Benefits|May 4, 2017
The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder PerspectivesSteven R Feldman, Bernard Goffe, Gary Rice, et al.
Arthritis Care & Research|August 30, 2018
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsPhilip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
The Journal of Sexual Medicine|November 13, 2018
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind StudyGil Yosipovitch, Peter Foley, Caitriona Ryan, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Arthritis Care & Research|October 27, 2017
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic StudyChristine Ballegaard, Tanja S Jørgensen, Marie Skougaard, et al.
Journal of the American Academy of Dermatology|October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trialsAlexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.
Annals of the Rheumatic Diseases|May 14, 2021
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyPhilip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, et al.
The Journal of Investigative Dermatology|February 1, 2020
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and PainAlice Gottlieb, Nicola E Natsis, Francisco Kerdel, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
American Health & Drug Benefits|May 4, 2017
The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder PerspectivesSteven R Feldman, Bernard Goffe, Gary Rice, et al.
Arthritis Care & Research|August 30, 2018
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsPhilip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
The Journal of Sexual Medicine|November 13, 2018
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind StudyGil Yosipovitch, Peter Foley, Caitriona Ryan, et al.
American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.
Arthritis Care & Research|October 27, 2017
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic StudyChristine Ballegaard, Tanja S Jørgensen, Marie Skougaard, et al.
Journal of the American Academy of Dermatology|October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trialsAlexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Plos One|June 16, 2011
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritisKnut M Wittkowski, Craig Leonardi, Alice Gottlieb, et al.
Annals of the Rheumatic Diseases|May 14, 2021
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyPhilip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, et al.
The Journal of Investigative Dermatology|February 1, 2020
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and PainAlice Gottlieb, Nicola E Natsis, Francisco Kerdel, et al.
Pageof 7